Spectral Medical Inc. (SD4.F)
- GlobeNewswire
Spectral Medical Provides Tigris Trial Update
101 patients enrolled TORONTO, April 10, 2024 (GLOBE NEWSWIRE) -- Spectral Medical Inc. (“Spectral” or the “Company”) (TSX: EDT), a late-stage theranostic company advancing therapeutic options for sepsis and septic shock, today provided an update on the Company’s Tigris trial, a Phase 3 follow-on study evaluating the use of Polymyxin B Hemoperfusion (“PMX”) in a randomized controlled trial of adults treated for endotoxemia and septic shock. Enrollment: Robust enrollment activity continues throug
- GlobeNewswire
Spectral Medical Chair to Retire From the Board of Directors
Dr. Paul Walker to succeed as ChairTORONTO, April 02, 2024 (GLOBE NEWSWIRE) -- Spectral Medical Inc. (“Spectral” or the “Company”) (TSX: EDT), a late-stage theranostic company advancing therapeutic options for sepsis and septic shock, today announced that Anthony (Tony) Bihl III, Spectral’s Chairman, will be retiring from the Board at Spectral’s upcoming Shareholder Meeting in June 2024. Mr. Bihl has been a Director of the Company for 16 years and was appointed to the role of Chairman in 2010. M
- Simply Wall St.
Spectral Medical Full Year 2023 Earnings: Misses Expectations
Spectral Medical ( TSE:EDT ) Full Year 2023 Results Key Financial Results Revenue: CA$1.60m (down 4.1% from FY 2022...
